At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
AZD8848 +1 moredrug
Likely dose
AZD8848 0.6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-controlled, Randomised, Parallel Group, Phase IIa Study to Investigate the Efficacy, Tolerability and Safety of 8 Doses of AZD8848 Administered Intranasally Once Weekly in Mild to Moderate Allergic Asthma Subjects Challenged With an Inhaled Allergen.
In Brief
A Phase 2 clinical trial evaluating AZD8848 and Placebo for Allergic Asthma. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total. The first part will investigate the tolerability and safety of AZD8848 while the second part will investigate both the therapeutic effect of AZD8848 and how well patients tolerate the drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Asthma
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedOct 2009
Primary CompletionFeb 2011
Study CompletionDec 2011
TodayJul 2026
First PostedOct 21, 2009
Enrollment StartOct 1, 2009
Primary CompletionFeb 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.7 years ago
Interventions
AZD8848drug
Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
Placebodrug
Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.